Australian-Canadian partnership for medical cannabis

LeafCann Group, a Melbourne-based medical cannabis producer, has formed a joint venture with Canadian developer of medical cannabis delivery systems and devices Resolve Digital Health.

The deal will grant LeafCann Group a licence to register and promote Resolve Digital Health’s proprietary Breeze Inhaler system in the Australian market. In addition, LeafCann Group and Resolve Digital Health will conduct clinical trials and pilot studies on the device and formulations in Australia.

LeafCann Group will retain an exclusive licence to sell and distribute the Breeze device for three years, with an option to extend. LeafCann Group will seek import licences for the Breeze Inhaler and pods for clinical trials and to meet demand from Australia’s Special Access Schemes, which allow for limited access to medical devices not yet registered on the Australian Register of Therapeutic Goods.

The global medical cannabis industry is estimated to reach $50 billion by 2025. In support of the growth of the industry in both Australia and Canada, LeafCann and Resolve will collaborate on a series of clinical trials that focus on symptom relief. Around the world, medical cannabis is prescribed for a plethora of medical conditions, including chronic pain, arthritis and joint disease, migraine headaches, cancer/chemotherapy, fibromyalgia, MS and many more.

“This agreement provides high-quality medical cannabis products and devices to the Australian market, to meet the needs of patients at end of life and those permitted to access medical cannabis products under Australia’s Special Access Schemes,” said LeafCann Group CEO Dr Jaroslav Boublik B.Sc.(Hons) Ph.D. (Med), MRACI, C.Chem. AACNEM, MICRS.